Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study

Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study

Abstract Background Intermittent treatment with TKIs is an option for the great majority (70%–80%) of CML patients who do not achieve a stable deep molecular response and are not eligible for treatment discontinuation. For these patients, the only alternative is to assume TKI continuously, lifelong....

Full description

Bibliographic Details
Main Authors: Michele Malagola, Alessandra Iurlo, Elisabetta Abruzzese, Massimiliano Bonifacio, Fabio Stagno, Gianni Binotto, Mariella D’Adda, Monia Lunghi, Monica Crugnola, Maria Luisa Ferrari, Francesca Lunghi, Fausto Castagnetti, Gianantonio Rosti, Roberto M. Lemoli, Rosaria Sancetta, Maria Rosaria Coppi, Maria Teresa Corsetti, Giovanna Rege Cambrin, Atelda Romano, Mario Tiribelli, Antonella Russo Rossi, Sabina Russo, Lara Aprile, Monica Bocchia, Lisa Gandolfi, Mirko Farina, Simona Bernardi, Nicola Polverelli, Aldo M. Roccaro, Antonio De Vivo, Michele Baccarani, Domenico Russo
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Cancer Medicine
Subjects:
chronic myeloid leukaemia
intermittent
quality of life
tyrosine kinase inhibitor
Online Access:https://doi.org/10.1002/cam4.3778

Internet

https://doi.org/10.1002/cam4.3778

Similar Items